Latest Cancer TreatmentsDr. Mohammadreza Dabiri
Dr. Mohammadreza Dabiriفارسی
Clinical tool

ELTS and Sokal Score Calculator in Chronic Myeloid Leukaemia (CML)

Prognosis at diagnosis to choose the tyrosine kinase inhibitor

Updated: 27 October 20261 min read3 references

ELTS score (prognosis for CML-related death in the tyrosine kinase inhibitor era) and Sokal score, at diagnosis before treatment.

This calculator needs JavaScript; the formula and its interpretation are in the text of this page.

An aid for clinicians; it does not replace clinical judgement, local protocols or the drug label. Double-check every result before prescribing.

Formulas

  • ELTS: 0.0025 × (age/10)3 + 0.0615 × spleen size (cm below the costal margin) + 0.1052 × peripheral blasts (%) + 0.4104 × (platelets/1000)−0.5, with platelets in 10⁹/L [1, 3]. Low: below 1.5680; intermediate: 1.5680–2.2185; high: above 2.2185 [3].
  • Sokal: exp[0.0116 × (age − 43.4) + 0.0345 × (spleen − 7.51) + 0.188 × ((platelets/700)2 − 0.563) + 0.0887 × (blasts − 2.10)]; below 0.8 low, 0.8–1.2 intermediate, above 1.2 high [2, 3]. It was developed before imatinib.

ELN 2020 prefers ELTS because it better predicts death from CML in the TKI era [3].

Record the values before any treatment (even hydroxyurea). Read more: CML treatment and life expectancy.

Related cancer types

Leukaemia

Treatment regimens (physicians)

BR regimen (bendamustine and rituximab)7+3 regimen (AML induction) and high-dose cytarabineAzacitidine with venetoclax in AMLTretinoin (ATRA) and arsenic trioxide in APLVenetoclax and obinutuzumab in CLL (the 12-month CLL14 regimen)

Physician tools and lessons

Cumulative Anthracycline Dose and Doxorubicin EquivalentsTumour Lysis Syndrome: Cairo-Bishop Criteria and PreventionHCT-CI Comorbidity Index Before Stem Cell TransplantationCLL-IPI Calculator (Chronic Lymphocytic Leukaemia Prognostic Index)IPSS-R Calculator for Myelodysplastic Syndromes (MDS)ELN 2022 Genetic Risk Classification of AMLIndications for haematopoietic stem cell transplantation, donor selection and conditioningGraft-versus-host disease (GVHD): prophylaxis, grading and treatment10 cheap steps that save patients' livesAcute myeloid leukaemia (AML): 2022 classification, ELN genetic risk and treatment

References

3 references
Show all references, 1 with a study cardClose the reference list

Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.

  1. 1
    Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemiaPfirrmann M, Baccarani M, Saussele S, et al · Leukemia · 2016;30:48-56
    DOIPubMed Back to text
  2. 2
    Prognostic discrimination in "good-risk" chronic granulocytic leukemiaSokal JE, Cox EB, Baccarani M, et al · Blood · 1984;63:789-99
    PubMed Back to text
  3. 3
    European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemiaHochhaus A, Baccarani M, Silver RT, et al · Leukemia · 2020;34:966-984
    Study cardDOIPubMed Back to text: 1 2 3 4

This page is based on reputable scientific sources and was last updated on 27 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.

Printed from the website; the full and up-to-date version: https://drdabiri.com/en/tools/cml-elts-sokal-calculator/

Related pages

27 October 2026 IPI, R-IPI, NCCN-IPI and CNS-IPI Calculator for DLBCL Calculator for the IPI, R-IPI, NCCN-IPI and CNS-IPI in diffuse large B-cell lymphoma (DLBCL) in the rituximab era. 27 October 2026 Follicular Lymphoma International Prognostic Index (FLIPI) Calculator FLIPI calculator for prognosis in follicular lymphoma and what it means for treatment decisions. 27 October 2026 International Prognostic Score (IPS) for Advanced Hodgkin Lymphoma IPS (Hasenclever score) calculator for advanced Hodgkin lymphoma and its place in current treatment.